Your browser doesn't support javascript.
Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests.
Kanji, Jamil N; Bailey, Ashley; Fenton, Jayne; Ling, Sean H; Rivera, Rafael; Plitt, Sabrina; Sligl, Wendy I; Taylor, Sean; Turnbull, LeeAnn; Tipples, Graham; Charlton, Carmen L.
  • Kanji JN; Division of Infectious Diseases, Department of Medicine, University of Alberta, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada; Department of Laboratory M
  • Bailey A; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada.
  • Fenton J; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada.
  • Ling SH; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada.
  • Rivera R; School of Public Health, University of Alberta, 3-003 Edmonton Clinic Health Academy, 11405-87 Avenue NW, Edmonton, AB T6G 1C9, Canada.
  • Plitt S; School of Public Health, University of Alberta, 3-003 Edmonton Clinic Health Academy, 11405-87 Avenue NW, Edmonton, AB T6G 1C9, Canada; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON K1A 0K9, Canada.
  • Sligl WI; Division of Infectious Diseases, Department of Medicine, University of Alberta, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada; Department of Critical Care Medicine, University of Alberta, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada.
  • Taylor S; GenScript USA Inc, 860 Centennial Avenue, Piscataway, NJ 08854, USA.
  • Turnbull L; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada.
  • Tipples G; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada; Li Ka Shing Institute of Virology, University of Alberta, 6-010 Katz Group Centre for Pharmacy and Health Research, Edmonton, AB T6G 2E1, Canada; Department o
  • Charlton CL; Public Health Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2B7, Canada; Department of Laboratory Medicine & Pathology, Faculty of Medicine and Dentistry, University of Alberta Hospital, 8440 - 112 Street NW, Edmonton, AB T6G 2
Vaccine ; 39(39): 5563-5570, 2021 09 15.
Article in English | MEDLINE | ID: covidwho-1411048
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

BACKGROUND:

With rapid approval of SARS-CoV-2 vaccines, the ability of clinical laboratories to detect vaccine-induced antibodies with available high-throughput commercial assays is unknown. We aimed to determine if commercial serology assays can detect vaccine-induced antibodies (VIAs) and understand the vaccination response.

METHODS:

This cohort study recruited healthcare workers and residents of long-term care facilities (receiving the BNT162b2 and mRNA-1273 products, respectively) who underwent serum collection pre-vaccination (BNT162b2 group), 2-weeks post vaccination (both groups), and pre-2nd dose (both groups). Sera were tested for the presence of SARS-CoV-2 IgG using four commercial assays (Abbott SARS-CoV-2 IgG, Abbott SARS-CoV-2 IgG II Quant, DiaSorin Trimeric S IgG, and GenScript cPASS) to detect VIAs. Secondary outcomes included description of post-vaccination antibody response and correlation with neutralizing titers.

RESULTS:

225 participants (177 receiving BNT162b2 and 48 receiving mRNA-1273) were included (median age 41 years; 66-78% female). Nucleocapsid IgG was found in 4.1% and 21.9% of the BNT162b2 (baseline) and mRNA-1273 (2-weeks post first dose). All anti-spike assays detected antibodies post-vaccination, with an average increase of 87.2% (range 73.8-94.3%; BNT162b2), and 25.2% (range 23.8-26.7%; mRNA-1273) between the first and last sampling time points (all p < 0.05). Neutralizing antibodies were detected at all post-vaccine timepoints for both vaccine arms, with increasing titers over time (all p < 0.05).

CONCLUSIONS:

Anti-spike vaccine-induced SARS-CoV-2 IgG are detectable by commercially available high-throughput assays and increases over time. Prior to second dose of vaccination, neutralizing antibodies are detectable in 73-89% of individuals, suggesting most individuals would have some degree of protection from subsequent infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Female / Humans / Male Language: English Journal: Vaccine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Female / Humans / Male Language: English Journal: Vaccine Year: 2021 Document Type: Article